Poppers and PrEP: Use of Pre-exposure Prophylaxis Among Men Who Have Sex with Men Who Use Inhaled Nitrites

被引:0
作者
H. Rhodes Hambrick
Su Hyun Park
John A. Schneider
Kenneth H. Mayer
Adam W. Carrico
Scott E. Sherman
Dustin T. Duncan
机构
[1] New York University School of Medicine,Spatial Epidemiology Lab, Department of Population Health
[2] University of Chicago School of Medicine,Departments of Medicine and Public Health Sciences
[3] and Chicago Center for HIV Elimination,Departments of Medicine and Global Health and Population
[4] Harvard Medical School and Harvard School of Public Health,Department of Public Health Sciences
[5] and Fenway Health,Department of Population Health, Spatial Epidemiology Lab
[6] Univeristy of Miami,undefined
[7] New York University School of Medicine,undefined
来源
AIDS and Behavior | 2018年 / 22卷
关键词
HIV prevention; Men who have sex with men; Poppers; Inhaled nitrites; PrEP;
D O I
暂无
中图分类号
学科分类号
摘要
Men who have sex with men (MSM) commonly use inhaled nitrites, or poppers, though their use is a risk factor HIV seroconversion. Pre-exposure prophylaxis, or PrEP, is effective for HIV prevention, but is not widely used, and little is known regarding PrEP use and acceptability among MSM who use inhaled nitrites. We surveyed 580 MSM in Paris, France in 2016 about popper use, sexual behaviors including condomless anal intercourse (CAI), serosorting, and sexual positioning, PrEP use, PrEP candidacy, and interest in alternate PrEP delivery modalities. We included 444 HIV negative participants for the current study. 46.2% reported popper use in the prior 3 months. Using multivariate adjusted logistic regression, we found that popper users were more likely than non-users to consider themselves candidates for PrEP [adjusted relative risk ratio (aRRR) = 2.73; 95% CI 1.54–4.83], but they were not more likely to be current (aRRR = 1.54; 95% CI 0.71–3.33) or past (aRRR = 1.37; 95% CI 0.44–4.28) PrEP users. Mediation analyses indicated that increased CAI and serosorting partly explained the relationship between popper use and PrEP candidacy. There was considerable interest in alternate proposed PrEP delivery modalities, particularly long-acting injectable PrEP [adjusted risk ratio (aRR) = 1.43; 95% CI 1.15–1.79].
引用
收藏
页码:3658 / 3672
页数:14
相关论文
共 256 条
[1]  
Marcus U(2009)Esitmating the size of the MSM populations for 38 European countries by calculating the survey-surveillance discrepancies (SSD) between self-reported new HIV diagnoses from the European MSM internet survey (EMIS) and surveillance-reported HIV diagnoses among MSM in 2009 BMC Public Health 13 919-2599
[2]  
Hickson F(2010)Preexposure chemophrophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2587-60
[3]  
Weatherburn P(2016)Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial Lancet 387 53-2246
[4]  
Schmidt AJ(2015)On-demand pre-exposure prophylaxis in men at high risk for HIV-1 infection N Engl J Med 373 2237-1964
[5]  
Grant RM(2012)Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals Cochrane Database Syst Rev 11 CD007189-829
[6]  
Lama JR(2013)The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies PLoS Med. 10 e1001401-557
[7]  
Anderson PL(2015)How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize “Truvada whores” Am J Public Health 105 1960-1062
[8]  
McMahan V(2014)Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study Lancet Infect Dis. 14 820-1555
[9]  
Liu AY(1998)Condom use as a dependent variable: measurement issues relevant to HIV prevention programs AIDS Educ Prev 10 548-250
[10]  
Vargas L(2012)Polling booth surveys: a novel approach for reducing social desirability bias in HIV-related behavioural surveys in resource-poor settings AIDS Behav 16 1054-218